Daniel E Falk, Megan L Ryan, Joanne B Fertig, Eric G Devine, Ricardo Cruz, E Sherwood Brown, Heather Burns, Ihsan M Salloum, D Jeffrey Newport, John Mendelson, Gantt Galloway, Kyle Kampman, Catherine Brooks, Alan I Green, Mary F Brunette, Richard N Rosenthal, Kelly E Dunn, Eric C Strain, Lara Ray, Steven Shoptaw, Nassima Ait-Daoud Tiouririne, Erik W Gunderson, Janet Ransom, Charles Scott, Lorenzo Leggio, Steven Caras, Barbara J Mason, Raye Z Litten
BACKGROUND: Several single-site alcohol treatment clinical trials have demonstrated efficacy for immediate-release (IR) gabapentin in reducing drinking outcomes among individuals with alcohol dependence. The purpose of this study was to conduct a large, multisite clinical trial of gabapentin enacarbil extended-release (GE-XR) (HORIZANT® ), a gabapentin prodrug formulation, to determine its safety and efficacy in treating alcohol use disorder (AUD). METHODS: Men and women (n = 346) who met DSM-5 criteria for at least moderate AUD were recruited across 10 U...
January 2019: Alcoholism, Clinical and Experimental Research